A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing ...

Danaher anticipates a strong 2026 due to its diagnostic portfolio being in highly attractive areas such as molecular testing, ...

GenomOncology (GO), a leader in precision medicine reporting solutions, today announced a strategic partnership with Oregon Health & Science University's (OHSU) Knight Diagnostics Lab (KDL) to enhance ...

The Center for Molecular Oncology at NYU Langone Health's Perlmutter Cancer Center will soon launch a new protocol for patients diagnosed with early-stage and advanced cancers, developing new ...

MIAMI, FL / ACCESS Newswire / December 17, 2025 / KIFFIK Biomedical announced today the successful close of its Series A financing, completed ahead of schedule and significantly oversubscribed. The ...

The molecular understanding of brain tumors has undergone a profound transformation in recent years. Advances in genomics, ...

5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partners New hospital-based data seeks to further differentiate pending kitted assay that measures ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market.

As we look ahead to 2026, we are continuing to execute on our strategy with purpose and momentum to create value for all our stakeholders.” OTI’s rapid self-test for CT/NG is built on the Sherlock ...

IMDX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of IMDX shares has decreased $0.34 since the market last closed. This is a 6.09% ...